Efficacy of Wobe-Mugos® E for reduction of oral mucositis after radiotherapy: Results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study

Strahlentherapie und Onkologie

Volumn 183, Issue 3, 2007, Pages 121-127

  Dörr, Wolfgang ^a   Herrmann, Thomas ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Fractionated irradiation; Mucoprotection; Oral mucositis; Proteolytic enzymes

Indexed keywords

CHYMOTRYPSIN; PAPAIN; PLACEBO; PROTEINASE; TRYPSIN; UNCLASSIFIED DRUG; WOBE MUGOS E;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; OROPHARYNX CARCINOMA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RADIATION INJURY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CHYMOTRYPSIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPAIN; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; STOMATITIS; TREATMENT FAILURE; TRYPSIN;

EID: 33847627872     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1634-0     Document Type: Article

References (32)

1. Antonadu D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:739-47.
2. Beaufort F. Reduzierung von Strahlennebenwirkungen durch hydrolytische Enzyme. Therapeutikon 1990;4:577-80.
3. Bentzen SM, Saunders MI, Dische S, et al. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001;60:123-35.
4. Christiansen H, Hermann RM, Martin A, et al. Neck lymph node metastases from an unknown primary tumor. Retrospective study and review of literature. Strahlenther Onkol 2005;181:355-62.
5. Demarosi F, Bez C, Carrassi A. Prevention and treatment of chemo- and radiotherapy-induced oral mucositis. Minerva Stomatol 2002;51:173-86.
6. Denham JW, Peters LJ, Johansen J, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol 1999;52:157-64.
7. Dobrowski W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000;57:119-24.
8. Dörr W. Three A's of repopulation during fractionated irradiation of squamous epithelia: asymmetry loss, acceleration of stem-cell divisions and abortive divisions. Int J Radiat Biol 1997;72:635-43.
9. Dörr W. Radiation-induced changes in ICAM-1 expression in mouse oral mucosa. DNA Repair 2000, Book of Abstracts, abstract 205.
10. Dörr W. Modulation of repopulation processes in oral mucosa: experimental results. Int J Radiat Biol 2003;79:531-7.
11. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001;61:223-31.
12. Dörr W, Herrmann T. Akute Strahlenveränderungen der Gewebe. In: Bamberg M, Molls M, Sack H, Hrsg. Radioonkologie, Bd 1: Grundlagen. Germering/München: Zuckschwerdt, 2003:244-50.
13. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Huntingt) 2003;17:1767-92.
14. Ernst E. Orale Therapie mit proteolytischen Enzymen: Effekte auf hämorheologische Parameter. Perfusion 1994;12:440-1.
15. Fleischer G, Dörr W. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine. Strahlenther Onkol 2006;182:567-75.
16. Gujral MS, Patnaik PM, Kaul R, et al. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 2001;47:Suppl:S23-8.
17. Kaanders JHAM, Pop LAM, Marres HAM, et al. ARCON. Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:769-78.
18. Kovacs AF, Mose S, Böttcher HD, et al. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol 2005;181:26-34.
19. Kunze R, Stauder G, Ransberger K, et al. Modulation of CD44 mediated adhesion of leukemic cells by hydrolytic enzymes. X. Internationale Tagung über Infektionen in der Gynäkologie und Geburtshilfe, München, März 1995.
20. Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell, 1987.
21. Martin T, Uhder K, Kurek R, et al. Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial. Radiother Oncol 2002;65:17-22.
22. Munzig E, Eckert K, Harrach T, et al. Bromelain proteinase reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett 1994;351:215-8.
23. Saadeh CE. Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment. Pharmacotherapy 2005;25:540-4.
24. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1. Pathogenesis and prophylaxis of mucositis. Head Neck 2003;25:1057-70.
25. Seegenschmiedt MH. Nebenwirkungen in der Onkologie. Internationale Systematik und Dokumentation. Berlin-Heidelberg: Springer, 1998.
26. Seeger AR, Windschall A, Lotter M, et al. The role of interstitial brachytherapy in the treatment of vaginal and vulvar malignancies. Strahlenther Onkol 2006;182:142-8.
27. Shih A, Miaskowski C, Dodd MJ, et al. A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncol Nurs Forum 2002;29:1063-80.
28. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8.
29. Stauder G, Beaufort F, Streichhan P. Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzympräparate. Dtsch Z Onkol 1991;23:7-16.
30. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000;47:1-12.
31. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253-62.
32. Velez I, Tamara LA, Mintz S. Management of oral mucositis induced by chemotherapy and radiotherapy: an update. Quintessence Int 2004;35:129-36.